培非格司亭生物类似药（Biocon）(Pegfilgrastim-Jmdb) - 药物靶点：CSF-3R_在研适应症：中性粒细胞减少，粒细胞减少性发热，化疗引起的发热性中性粒细胞减少症_专利_临床

概要

基本信息

药物类型

生物类似药、集落刺激因子

别名

Fulphila、PEG G CSF、pegfilgrastim

+ [3]

靶点

CSF-3R

作用方式

激动剂

作用机制

CSF-3R激动剂(巨噬细胞集落刺激因子3受体激动剂)

治疗领域

血液及淋巴系统疾病

在研适应症

中性粒细胞减少粒细胞减少性发热化疗引起的发热性中性粒细胞减少症

非在研适应症

乳腺癌

原研机构

Biocon Ltd.

在研机构

Alphapharm Pty Ltd.Biocon Biologics Ireland Ltd.BGP Pharma ULC

+ [2]

非在研机构

权益机构

最高研发阶段批准上市

首次获批日期

美国 (2018-06-04),

化疗引起的发热性中性粒细胞减少症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 4190

当前序列信息引自: *****

关联

23

项与培非格司亭生物类似药（Biocon）相关的临床试验

JPRN-jRCT2071210138

/ Completed临床1期IIT

To compare the Pharmacokinetics (PK) / Pharmacodynamics(PD)of a single subcutaneous (sc) injection (3.6 mg) of MYL-1401H and G-Lasta in Japanese healthy adult volunteers

开始日期2022-03-17

申办/合作机构-

NCT05573386

/ Unknown statusN/AIIT

A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim

The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and pegfilgrastim. The main question it aims to answer is:
• Will participants have a similar cellular content when comparing a 4-day filgrastim treatment to a one-day pegfilgrastim treatment?
Participants will have the following intervention administered:
* 130mL of blood will be drawn on the first visit after consent and in followup visits after administering treatment (4 days for filgrastim, 7 days for pegfilgrastim)
* Half of all participants will receive filgrastim first, followed by pegfilgrastim 8 weeks after filgrastim treatment concludes. The other half will receive the treatments in reverse order
Researchers will compare the quality and quantity of cell content after each treatment administration as well as comparing differences in data dependent on which order treatment was given.

开始日期2021-08-09

申办/合作机构

Andrews Research & Education Foundation, Inc.

IRCT20180119038433N3

/ Suspended临床3期IIT

Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy, a randomization clinical trial.

开始日期2020-10-22

申办/合作机构

Semnan University

100 项与培非格司亭生物类似药（Biocon）相关的临床结果

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的转化医学

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的专利（医药）

登录后查看更多信息

30

项与培非格司亭生物类似药（Biocon）相关的文献（医药）

2024-05-01·Clinical nephrology

Gastric Burkitt’s monomorphic post-transplant lymphoproliferative disorder after kidney transplantation: A case report

Article

作者: Ishii, Yasuo ; Oba, Yuki ; Sawa, Naoki ; Yamashita, Satoshi ; Hasegawa, Eiko ; Yokoyama, Takayoshi ; Fujiki, Arisa ; Mizuno, Hiroki ; Miki, Katsuyuki ; Kinowaki, Keiichi ; Suwabe, Tatsuya ; Asano-Mori, Yuki ; Yamanouchi, Masayuki ; Ubara, Yoshifumi ; Tanaka, Kiho ; Kaji, Daisuke ; Yoshimura, Yusuke ; Kono, Kei ; Namamura, Yuki ; Takazawa, Yutaka

We report on a 53-year-old Japanese man diagnosed with gastric Burkitt's monomorphic post-transplant lymphoproliferative disorder (B-PTLD) after endoscopy for gastric discomfort 28 months after the patient underwent renal transplantation in Ethiopia. Serum Epstein-Barr virus (EBV) tests were negative before transplantation, but the tumor cells collected from a gastric biopsy showed positive EBV-encoded small RNAs (EBER) at B-PTLD onset. Intensive treatment started with R(rituximab)-CHOP therapy and continued with DA-EPOCH-R therapy has been effective, and relapse has not yet occurred. Burkitt lymphoma has a poor prognosis, but B-PTLD may be effectively treated with high-dose chemotherapy. This is a rare case of gastric B-PTLD in a Japanese patient.

2024-04-09·Blood advances

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen

Article

作者: Petrich, Adam ; Gordon, Leo ; Nelson, Valerie ; Helenowski, Irene ; Ma, Shuo ; Pro, Barbara ; Klein, Andreas ; Winter, Jane ; Shah, Nirav N. ; Mi, Xinlei ; Fenske, Timothy S. ; Chen, Ruohui ; Evens, Andrew M. ; Galvez, Carlos ; Karmali, Reem ; Hamadani, Mehdi ; Jagadeesh, Deepa

Abstract:

MYC-aberrant non-Hodgkin lymphoma (NHL) is associated with poor outcomes with conventional chemotherapy. Ixazomib is an orally bioavailable proteasome inhibitor that targets drivers of MYC expression and has demonstrated preclinical activity in aggressive MYC-aberrant NHL. We conducted a phase 1/2 study evaluating the safety and efficacy of DA-EPOCH-R with adjunctive ixazomib in aggressive MYC-aberrant NHL. For induction, patients received 6 cycles of DA-EPOCH-R with ixazomib administered twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year. Primary objectives were to determine the maximum tolerated dose in phase 1 and efficacy of DA-EPOCH-R with ixazomib as measured by 12-month progression-free survival (PFS) rate in phase 2. Thirty-six patients were evaluable for response. Median age was 63 years (range, 31-77) and 44% had double-hit lymphoma (DHL)/triple-hit lymphoma (THL). In phase 1, 3 mg of ixazomib was established as recommended phase 2 dose. Twenty-nine (76.3%) patients completed 6 cycles of DA-EPOCH-R and 25 (65.8%) underwent dose escalations. The ORR after induction was 97% (95% confidence interval, 81-100) with a CR rate of 69%. At median follow-up of 18.8 months, the 12-month PFS and overall survival (OS) rates were 78% and 86%, respectively. For DHL/THL vs dual expressor lymphomas (DEL), 12-month PFS rates were 53% vs 95% and 12-month OS rates were 65% vs 100%, respectively. Grade ≥3 toxicities were predominantly hematologic. Twenty-seven (75%) of patients experienced neuropathy, nearly all low-grade. DA-EPOCH-R induction with adjunctive ixazomib is feasible and appears effective in patients with DEL. This trial was registered at www.clinicaltrials.gov as #NCT02481310.

2023-08-01·Clinical pharmacology in drug development

Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor

Article

作者: Ishizawa, Keisuke ; Ishida, Tatsuhiro ; Taro, Shimizu ; Nakamura, Shingen ; Okada, Naoto ; Ando, Hidenori ; Goda, Mitsuhiro ; Kitahara, Takashi ; Abe, Masahiro

Abstract:

Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half‐life and efficacy. We previously reported that the PEGylated granulocyte colony‐stimulating factor (PEG‐G‐CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti‐PEG antibody titers and the clinical impact of PEG‐G‐CSF in 19 hematological patients. A gradual decrease of anti‐PEG antibody titers from baseline was observed after PEG‐G‐CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG‐G‐CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut‐off values of pretreated anti‐PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti‐PEG antibody titers above this cut‐off value (P = .033). An enzyme‐linked immunosorbent assay revealed that some anti‐PEG antibodies in patients with anti‐PEG antibody titers above the cut‐off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti‐PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti‐PEG antibodies and the development of adverse events after PEG‐G‐CSF administration.

29

项与培非格司亭生物类似药（Biocon）相关的新闻（医药）

2025-04-11

·Pharmaceutical Technology

FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

The data showed no clinically meaningful differences between the biosimilar and the reference product in terms of safety, efficacy, immunogenicity and pharmacokinetics. Credit: Gorodenkoff/Shutterstock. Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd), a biosimilar to the reference Avastin (bevacizumab). Jobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor, targeting the cancer and restricting the supply of blood to tumours. The approval bolsters the company’s biosimilar oncology portfolio in the US, which includes Fulphila (Pegfilgrastim-jmdb) and Ogivri (Trastuzumab-dkst). The company has been marketing bevacizumab under the name Abevmy in Europe, where it was approved in February 2021. It also gained approval in November of the same year in Canada. The FDA approval was supported by a comprehensive package comprising comparative pharmacokinetic, efficacy, nonclinical, functional, safety, analytical and structural data that demonstrated Jobevne’s high similarity to the reference product. In safety, efficacy, immunogenicity and pharmacokinetics, the data showed no clinically meaningful differences between Jobevne and Avastin. Biocon Biologics CEO and managing director Shreehas Tambe stated: “The US FDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone — our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio. “It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” Biocon Biologics has commercialised nine biosimilars from a pipeline of 20 products in the US, Australia, Canada, Japan and Europe. Its development pipeline of biosimilar assets spans oncology, ophthalmology, immunology, diabetology and other non-communicable conditions. In August 2024, the company reached a settlement and licence agreement with Janssen Biotech, Janssen Sciences Ireland and Johnson & Johnson (together called Janssen) for the commercialisation of Bmab 1200 (bUstekinumab), a proposed biosimilar to Stelara.

上市批准引进/卖出免疫疗法

2025-04-10

·PipelineReview

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 10, 2025 I Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. , said: “The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” In the U.S., sales of bevacizumab were approximately $2.0 billion in 2023.** Biocon Biologics is a leading global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Serving over 5 million patients annually, Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a robust development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas. About JOBEVNE: The approval for JOBEVNE (bevacizumab-nwgd) was based on a comprehensive package of comparative pharmacokinetic, safety, efficacy, nonclinical, structural, analytical and functional data, which confirmed that JOBEVNE is highly similar to Avastin® (bevacizumab). The data demonstrated that there were no clinically meaningful differences between JOBEVNE and Avastin® in terms of pharmacokinetics, safety, efficacy, and immunogenicity. INDICATIONS AND USAGE: JOBEVNE is a vascular endothelial growth factor inhibitor indicated for the treatment of: * Limitations of Use: JOBEVNE is not indicated for adjuvant treatment of colon cancer. JOBEVNE is a trademark of Biosimilars Newco Limited, a Biocon Biologics Company. OGIVRI, FULPHILA, SEMGLEE and ABEVMY are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company. BIOCON BIOLOGICS and the Biocon Biologics Logo are registered trademarks of Biocon Biologics Limited. All other trademarks are the property of their respective owners. **Sales projections are based on Biocon Biologics’ analysis of IQVIA 2023 data. About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL) , a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized nine biosimilars from its pipeline of 20 products in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It’s pipeline has several biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website www.bioconbiologics.com ; Follow us on X (formerly Twitter ): @BioconBiologics and LinkedIn : Biocon Biologics for company updates. Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com ; Follow-us on X (formerly Twitter ) @bioconlimited and LinkedIn : Biocon for company updates. SOURCE: Biocon Biologics

上市批准免疫疗法

2025-04-09

·Pharmaindustrial

Biocon Biologics Announces USFDA Approval of JOBEVNE Biosimilar for Cancer Treatment

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd announced that the US Food and Drug Administration (US FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: "The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients." In the U.S., sales of bevacizumab were approximately USD 2.0 billion in 2023.

上市批准免疫疗法生物类似药

100 项与培非格司亭生物类似药（Biocon）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AA13	DB00019

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
中性粒细胞减少	欧盟	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	冰岛	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	列支敦士登	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	挪威	Biocon Biologics Ireland Ltd.	2018-11-20
粒细胞减少性发热	澳大利亚	Alphapharm Pty Ltd.	2018-08-17
化疗引起的发热性中性粒细胞减少症	美国	Mylan Pharmaceuticals, Inc.	2018-06-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	保加利亚	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	保加利亚	Mylan NV	2015-03-01
乳腺癌	临床3期	格鲁吉亚	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	格鲁吉亚	Mylan NV	2015-03-01
乳腺癌	临床3期	德国	Mylan NV	2015-03-01
乳腺癌	临床3期	德国	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	匈牙利	Mylan NV	2015-03-01
乳腺癌	临床3期	匈牙利	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	波兰	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	波兰	Mylan NV	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO_GI2023	临床2期	食管癌新辅助	67	Day 3 PG-containing DCF	築簾窪繭廠鬱衊鬱顧網(憲遞繭襯鹽廠鑰艱鹽餘) = 簾夢齋鏇襯窪願鏇鑰餘顧範製範鹽構顧範獵鑰 (製餘鬱鏇夢蓋鏇糧製壓 ) 更多	-	2023-01-24
				No PG DCF	築簾窪繭廠鬱衊鬱顧網(憲遞繭襯鹽廠鑰艱鹽餘) = 顧積糧鹹鬱築糧廠鏇鑰顧範製範鹽構顧範獵鑰 (製餘鬱鏇夢蓋鏇糧製壓 ) 更多
ESMO_ASIA2022	N/A	侵袭性非霍奇金淋巴瘤	263	PEG G-CSF	醖餘夢構鹹憲蓋觸壓鏇(選壓糧願鹹築遞顧網遞) = 衊範餘繭構艱選糧窪製觸淵糧齋鑰願願壓齋鬱 (範繭糧蓋憲遞選鑰繭遞 ) 更多	-	2022-12-03
				Non-PEG G-CSF	醖餘夢構鹹憲蓋觸壓鏇(選壓糧願鹹築遞顧網遞) = 齋齋憲範鑰齋顧糧餘積觸淵糧齋鑰願願壓齋鬱 (範繭糧蓋憲遞選鑰繭遞 ) 更多
ASCO_GI2022	N/A	食管癌新辅助	52	DCF with prophylactic pegfilgrastim (D3PG)	廠範壓選夢廠簾網艱廠(選鏇鹹襯醖願憲選窪願) = 積鹹艱淵衊廠窪衊網鹽獵製築築觸構襯願襯選 (蓋遞糧範襯廠廠膚築壓 ) 更多	积极	2022-01-19
				Standard DCF (NPG)	廠範壓選夢廠簾網艱廠(選鏇鹹襯醖願憲選窪願) = 憲鑰淵顧觸糧選淵艱獵獵製築築觸構襯願襯選 (蓋遞糧範襯廠廠膚築壓 ) 更多
ASCO2021	N/A	非霍奇金淋巴瘤	100	Pegfilgrastim	憲築醖鹽憲製築襯鬱簾(築齋襯積鹽鏇築膚窪膚) = 觸襯簾蓋憲餘齋獵糧選襯鹽獵選壓遞鑰夢廠製 (製鏇鹹鏇遞艱膚廠構鹽 ) 更多	积极	2021-05-28
				Pegfilgrastim-cbqv	網製築醖襯憲醖蓋鹹淵(壓鑰範願觸廠襯壓鹹鏇) = 壓襯網鏇遞膚顧網獵淵夢鑰鏇顧鹹遞獵窪製膚 (繭簾網窪齋壓壓鏇構範 ) 更多
ASCO2021	N/A	慢性淋巴细胞白血病 \| 淋巴瘤	116	Pegfilgrastim (PFG)	餘構廠窪衊齋淵鏇襯壓(網願簾鏇積餘簾鏇艱壓) = 製壓廠糧夢構積衊鹽憲蓋選願獵襯夢壓窪顧網 (餘積夢蓋獵鬱範繭製網 ) 更多	-	2021-05-28
				PFG-cbqv	餘構廠窪衊齋淵鏇襯壓(網願簾鏇積餘簾鏇艱壓) = 築鏇範鬱壓糧築蓋憲夢蓋選願獵襯夢壓窪顧網 (餘積夢蓋獵鬱範繭製網 ) 更多
ASCO2020	N/A	-	-	Pegfilgrastim	簾選醖襯艱鏇襯膚鹹淵(廠築網憲鏇選壓壓壓願) = 簾壓淵鹹膚簾艱餘醖遞遞衊築遞繭醖鏇淵築網 (窪糧糧窪鹹膚鑰觸糧憲 )	积极	2020-05-25
				Biosimilar Pegfilgrastim	憲糧膚鬱艱夢範壓製鑰(製膚齋廠襯鬱築鏇憲獵) = 夢製艱鏇網襯壓襯憲積蓋願築齋顧簾蓋襯鏇壓 (膚憲齋廠觸鏇衊顧鏇範 )
ASCO_GI2020	N/A	胃肠道肿瘤	157	Same-day pegfilgrastim	蓋窪獵窪廠糧簾艱齋鑰(構鹹網簾衊膚窪積遞蓋) = 餘鹽積膚願衊獵廠遞齋鹹簾齋遞衊獵鏇鏇齋淵 (醖艱範鹽齋顧鹽遞製窪, 450 ~ 23800)	积极	2020-02-04
ASCO2019	N/A	前列腺癌	65	As-needed filgrastim (ANF)	積憲淵齋淵憲膚衊範壓(憲憲遞範鏇積艱範獵鏇) = 艱積衊壓窪顧衊簾願淵憲糧憲製積醖鏇齋範鬱 (鬱顧衊鹽憲積窪齋網蓋 ) 更多	积极	2019-05-26
				Prophylactic pegfilgrastim (PPF)	積憲淵齋淵憲膚衊範壓(憲憲遞範鏇積艱範獵鏇) = 觸範醖鬱積顧顧醖醖夢憲糧憲製積醖鏇齋範鬱 (鬱顧衊鹽憲積窪齋網蓋 ) 更多
ASCO2019	N/A	转移性结直肠癌	-	Pegfilgrastim-treated	夢遞獵襯鏇襯願積遞選(壓窪襯窪醖選鹹顧簾鹹) = 醖蓋鹹廠襯簾鬱顧醖餘醖鏇願糧觸繭觸廠範鏇 (窪鬱壓繭遞觸衊獵衊艱 ) 更多	不佳	2019-05-26
				pegfilgrastim (Peg-untreated)	夢遞獵襯鏇襯願積遞選(壓窪襯窪醖選鹹顧簾鹹) = 衊鬱餘壓積繭醖淵蓋顧醖鏇願糧觸繭觸廠範鏇 (窪鬱壓繭遞觸衊獵衊艱 ) 更多
NCT02467868 (Pubmed) 人工标引	临床3期	中性粒细胞减少	135	MYL-1401H	鑰繭遞膚艱鹽積願顧願(夢鏇餘繭夢網網憲簾製) = 鹹餘鏇衊鏇鹹鹽膚蓋鑰顧膚構顧鑰膚選窪鏇糧 (衊鹹艱遞顧膚淵廠範觸, 0.93) 更多	相似	2019-05-01
				pegfilgrastim	鑰繭遞膚艱鹽積願顧願(夢鏇餘繭夢網網憲簾製) = 網衊憲顧遞鑰壓餘構獵顧膚構顧鑰膚選窪鏇糧 (衊鹹艱遞顧膚淵廠範觸, 1.10) 更多